Because our results here support a role for miR‐18a in the regulation of PIAS3 protein expression in MM cell lines, we investigated its potential role as a therapeutic target in MM cells by inhibiting miR‐18a in cells and by determining its clinical importance in MM patient survival using the TCGA database (https://cancergenome.nih.gov/). Here, PIAS3 is linked to Miyoshi myopathy.